{"id":37257,"date":"2025-07-14T12:11:36","date_gmt":"2025-07-14T04:11:36","guid":{"rendered":"https:\/\/flcube.com\/?p=37257"},"modified":"2025-07-14T12:11:37","modified_gmt":"2025-07-14T04:11:37","slug":"carsgen-therapeutics-secures-european-patent-for-gpc3-car-t-technology-after-successful-opposition-proceedings","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37257","title":{"rendered":"CARsgen Therapeutics Secures European Patent for GPC3 CAR-T Technology After Successful Opposition Proceedings"},"content":{"rendered":"\n

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171<\/a>) announced a favorable outcome in the opposition proceedings for its European Patent EP3445407 before the European Patent Office (EPO). The patent covers the company’s proprietary GPC3-targeted CAR-T cell therapy technology.<\/p>\n\n\n\n

Opposition Proceedings and Appeal Withdrawal<\/strong>
A U.S. biotechnology company\u2014the sole appellant among the two original opponents\u2014formally withdrew its appeal earlier this week. This action renders the EPO Opposition Division’s decision to maintain the patent validity (in amended form) final and binding on all opponents, effectively concluding the opposition proceedings.<\/p>\n\n\n\n

Patent Details and Scope<\/strong>
The patent was granted by the EPO in 2022 and received oppositions from two parties in 2023. After oral proceedings, the EPO Opposition Division decided to maintain the patent in amended form. The upheld key claims cover the use of GPC3 CAR-T cells to treat hepatocellular carcinoma, lung cancer, ovarian cancer, breast cancer, gastric cancer, and thyroid cancer following lymphodepletion pretreatment with cyclophosphamide and fludarabine.<\/p>\n\n\n\n

Conclusion of Legal Challenges<\/strong>
After the decision was issued, only one opponent filed an appeal within the statutory time limit, and this appeal has now been formally withdrawn. According to EPO procedures, the opponents and any other third parties can no longer challenge this patent through EPO channels.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced a favorable outcome in the opposition proceedings…<\/p>\n","protected":false},"author":1,"featured_media":37259,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,61],"tags":[379,1188,73],"class_list":["post-37257","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-legal-ip","tag-carsgen-therapeutics","tag-hkg-2171","tag-patents"],"yoast_head":"\nCARsgen Therapeutics Secures European Patent for GPC3 CAR-T Technology After Successful Opposition Proceedings - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced a favorable outcome in the opposition proceedings for its European Patent EP3445407 before the European Patent Office (EPO). The patent covers the company's proprietary GPC3-targeted CAR-T cell therapy technology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37257\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CARsgen Therapeutics Secures European Patent for GPC3 CAR-T Technology After Successful Opposition Proceedings\" \/>\n<meta property=\"og:description\" content=\"China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced a favorable outcome in the opposition proceedings for its European Patent EP3445407 before the European Patent Office (EPO). The patent covers the company's proprietary GPC3-targeted CAR-T cell therapy technology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37257\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-14T04:11:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-14T04:11:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1404.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37257#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37257\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CARsgen Therapeutics Secures European Patent for GPC3 CAR-T Technology After Successful Opposition Proceedings\",\"datePublished\":\"2025-07-14T04:11:36+00:00\",\"dateModified\":\"2025-07-14T04:11:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37257\"},\"wordCount\":223,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37257#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1404.webp\",\"keywords\":[\"CARsgen Therapeutics\",\"HKG: 2171\",\"Patents\"],\"articleSection\":[\"Company\",\"Legal \\\/ IP\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37257#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37257\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37257\",\"name\":\"CARsgen Therapeutics Secures European Patent for GPC3 CAR-T Technology After Successful Opposition Proceedings - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37257#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37257#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1404.webp\",\"datePublished\":\"2025-07-14T04:11:36+00:00\",\"dateModified\":\"2025-07-14T04:11:37+00:00\",\"description\":\"China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced a favorable outcome in the opposition proceedings for its European Patent EP3445407 before the European Patent Office (EPO). The patent covers the company's proprietary GPC3-targeted CAR-T cell therapy technology.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37257#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37257\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37257#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1404.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1404.webp\",\"width\":1080,\"height\":608,\"caption\":\"CARsgen Therapeutics Secures European Patent for GPC3 CAR-T Technology After Successful Opposition Proceedings\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37257#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CARsgen Therapeutics Secures European Patent for GPC3 CAR-T Technology After Successful Opposition Proceedings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CARsgen Therapeutics Secures European Patent for GPC3 CAR-T Technology After Successful Opposition Proceedings - Insight, China's Pharmaceutical Industry","description":"China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced a favorable outcome in the opposition proceedings for its European Patent EP3445407 before the European Patent Office (EPO). The patent covers the company's proprietary GPC3-targeted CAR-T cell therapy technology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37257","og_locale":"en_US","og_type":"article","og_title":"CARsgen Therapeutics Secures European Patent for GPC3 CAR-T Technology After Successful Opposition Proceedings","og_description":"China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced a favorable outcome in the opposition proceedings for its European Patent EP3445407 before the European Patent Office (EPO). The patent covers the company's proprietary GPC3-targeted CAR-T cell therapy technology.","og_url":"https:\/\/flcube.com\/?p=37257","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-14T04:11:36+00:00","article_modified_time":"2025-07-14T04:11:37+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1404.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37257#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37257"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CARsgen Therapeutics Secures European Patent for GPC3 CAR-T Technology After Successful Opposition Proceedings","datePublished":"2025-07-14T04:11:36+00:00","dateModified":"2025-07-14T04:11:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37257"},"wordCount":223,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37257#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1404.webp","keywords":["CARsgen Therapeutics","HKG: 2171","Patents"],"articleSection":["Company","Legal \/ IP"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37257#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37257","url":"https:\/\/flcube.com\/?p=37257","name":"CARsgen Therapeutics Secures European Patent for GPC3 CAR-T Technology After Successful Opposition Proceedings - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37257#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37257#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1404.webp","datePublished":"2025-07-14T04:11:36+00:00","dateModified":"2025-07-14T04:11:37+00:00","description":"China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced a favorable outcome in the opposition proceedings for its European Patent EP3445407 before the European Patent Office (EPO). The patent covers the company's proprietary GPC3-targeted CAR-T cell therapy technology.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37257#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37257"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37257#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1404.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1404.webp","width":1080,"height":608,"caption":"CARsgen Therapeutics Secures European Patent for GPC3 CAR-T Technology After Successful Opposition Proceedings"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37257#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CARsgen Therapeutics Secures European Patent for GPC3 CAR-T Technology After Successful Opposition Proceedings"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1404.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37257"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37257\/revisions"}],"predecessor-version":[{"id":37260,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37257\/revisions\/37260"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37259"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}